Overview
Multidisciplinary Team Strategies for Managing Tardive Dyskinesia
Multimedia, Digital Newsletter!
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Dive into this engaging digital newsletter created by our multidisciplinary faculty panel, Christoph Correll, MD and Rose Mary Xavier, PhD, MS, RN, PMHNP-BC to learn proper recognition and management of tardive dyskinesia (TD). This newsletter provides guidance on diagnostic criteria, treatment algorithms, as well as strategies for how to incorporate novel therapies while ensuring optimal adherence and patient quality of life.
This educational activity is designed for psychiatrists, PAs, NPs, APRNs, nurses, and other allied healthcare professionals interested in treatment and management of neurological disorders.
TD is widespread in the psychiatric population and in other populations that commonly receive dopamine antagonists and/or other therapies that are associated with TD. However, patients receiving these drugs are often not counseled on the risk of developing TD as a direct result of their prescribed therapies. Clinicians prescribing therapies associated with TD need to recognize risk factors to help minimize TD and its consequences. In addition, the heterogeneity of patients with TD, the wide variability of treatment response for concomitant conditions, and lack of treatment standards for TD mean that many, if not most, patients with TD have uncontrolled symptoms that are detrimental to their quality of life and activities of daily living. Patients may not adhere to psychiatric and other neuroleptic therapies due to the emergence of TD symptoms. Further, differential diagnosis of TD versus similar conditions is complex, challenging, and current epidemiological data indicate that clinicians lack familiarity to the latest diagnostic criteria to help identify patients at increased risk for TD. Finally, novel therapies specifically indicated for TD have only recently been approved. Clinicians require continuing education on these newer agents and their roles and implications for TD care. Problematically, many patients with TD continue to take suboptimal off-label therapies despite the emergence of these newer treatments, further underscoring the need for education.
Upon completion of this activity, participants will be able to:
• Evaluate multidisciplinary strategies to identify possible patient population(s) that may be at increased risk for tardive dyskinesia
• Discuss the consequences of tardive dyskinesia that may decrease a patient's quality of life and adherence to treatment for concomitant disorders
• Recognize the risks and possible complications associated with managing tardive dyskinesia with off-label therapies
• Describe current differential diagnostic and evidence-based treatment algorithms for patients with tardive dyskinesia
• Interpret the clinical trial efficacy and safety data of novel and emerging therapies for tardive dyskinesia
Chapter 1: Overview of Tardive Dyskinesia (TD)
• Presentation
• Risk Factors
Chapter 2: Navigating Challenges
• Diagnostic Criteria
• Current Challenges
• Comorbidities
• Clinician Video Commentary: Practical Diagnostic Guidance for Clinicians
Chapter 3: Evidence-based Management of TD
• Available Therapies
• Clinician Video Commentary: Distinguishing the Newer TD Agents
• Adverse Events
• Treatment Selection and Dosing
Chapter 4: Partnering with Patients to Improve Outcomes
• QoL and Daily Functioning Challenges
• Clinician Video Commentary: Improving Patient Outcomes and Quality of Life
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Teva Pharmaceuticals.
Christoph U. Correll, MD (Chair)
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
Professor of Psychiatry
The Zucker Hillside Hospital
New York, NY
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
Professor of Psychiatry
The Zucker Hillside Hospital
New York, NY
Rose Mary Xavier, PhD, MS, RN, PMHNP-BC (Nurse Planner)
Assistant Professor
UNC Chapel Hill School of Nursing
Adult Psychiatric Mental Health Nurse Practitioner
Chapel Hill, NC
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
The following financial relationships have been provided:
Christoph U. Correll, MD
Advisor, Consulting Agreements, and/or Honorarium Recipient: Acadia; Alkermes; Allergan; Angelini;
Axsome; Gedeon Richter; Indivior; IntraCellular Therapies; Janssen/J&J; LB Pharma; Lundbeck; MedAvante-ProPhase; Merck & Company; Mylan; Neurocrine; Noyen; Otsuka; Pfizer, Inc.; Recordati; Rovi; Servier; Sumitomo Dainippon; Sunovion; Supernus; Takeda; and Teva Pharmaceuticals
Expert Testimony: Janssen; Otsuka
Data Safety Monitoring Board: Lundbeck; Rovi; Supernus; and Teva Pharmaceuticals
Grants/Research Support: Janssen; Takeda
Stock Shareholder: LB Pharma
Rose Mary Xavier, PhD, MS, RN, PMHNP-BC has nothing to disclose.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Biperiden, trihexyphenidyl, benztropine, procyclidine, amantadine, clonazepam, propranolol, tetrabenazine, levetiracetam, zonisamide, and nutritional supplements (eg, branch-chain amino acids, Yi-gin san, gingko biloba, melatonin, omega-3 fatty acids, resveratrol, vitamin B6, and vitamin E).
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.
This nursing continuing professional development activity was approved by the American Association of Neuroscience Nurses, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Completion of this activity including the pre, post, and follow-up assessments qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
